3SOF

DYNT will likely report very strong numbers for 3Q 2006 during the first week of May. The stock has undergone heavy accumulationj and it is not ready to roar:

http://stockcharts.com/gallery/?dynt

DYNT is the leader in the area of light therapy for pain management. Light therapy has been approved by the FDA. One of Dynatronics' light therapy probes were use to accelerate Terrel Owens' amazing recovery in time to play in the Superbowl a couple of years ago.

DYNT has started shipping several new pain-management products in recent months and are expected to boost revenues and net income starting this quarter. DYNT had never before launched so many new products before. Revenue and net income usually jump in the quarters following the deployment of new products.

DYNT is grossly undervalued. DYNT is a consistently profitable company with a strong balance sheet. With a parket cap of only $15M, it is currently trading at a ridiculous P/S 0f 0.6.

Because light therapy is non-invasive and does not have adverse effects, it is an ideal replacement for dangerous drugs like Vioxx, and Celebrex to address Rheumatism and similar types of pain. Light therapy is also used for carpal syndrome and a number of muscle/nerve/bone types of pain.

Light Therapy has been used extensively throughout the world for more than twenty years. Also known as cold laser or phototherapy, Light Therapy is backed by extensive research with over 500 published studies covering a number of soft-tissue injuries, pain, and inflammatory conditions.

DYNT has introduced a number of new state-of-the-art pain management products at the end of last quarter and this quarter:

Dynatronics began shipping three new products during the second quarter, including the Dynatron Xp infrared light pad. This innovative product is 14 times more powerful than infrared light probes currently on the market. It is capable of treating a much larger area than can be treated by competitors' devices. Importantly, it makes unattended patient therapy possible, allowing practitioners to treat multiple patients simultaneously. The other two products introduced during the second quarter were the Dynatron iBox iontophoresis device and the D880Plus infrared light probe.

"Looking ahead to the third quarter, we are pleased to report that we have already begun shipping the Dynatron 702, a stand-alone light therapy device," said Larry K. Beardall, executive vice president of sales and marketing. "The new Dynatron 702 not only simplifies infrared light therapy treatments, but can be combined with our traction device for dual therapy treatments."

An additional third quarter product introduction -- the DX9 combination traction and light therapy system -- also began shipping in January. The new Dynatron DX9 Decompression System combines the benefits of infrared light therapy with decompression therapy for treating back pain. Decompression therapy is commonly used to relieve the pain associated with a number of back problems, including herniated discs, degenerative disc disease, sciatica and pinched nerves.

Other new products currently under development include the Dynatron X3 multiple modality infrared light therapy device, the DX2 proprietary traction device that incorporates unique technology, and the T4 therapy table specially designed for performing traction and decompression therapies. These products will expand the range of decompression and light therapy treatment options for treating back pain.

"The introduction of these state-of-the-art products will give additional impetus to the growth of sales and profits in future quarters," added CEO Cullimore.


Insiders have been loading up lately as you can see in the following link:

http://www.secform4.com/insider/show...y.php?cik=dynt

Big buyers are lining up on the bid. DYNT could start takung off from here. Technicals and fundamentals are just right for a major explosion.

I expect record earnings this time. The new products that DYNT has launched the last two quarters will start showing up in the top and bottom lines this quarter ....and the subsequent quarters.

BEST QUARTER IN A WHILE FOR ALL THREE COMPANIES NEXT WEEK. POTENTIAL 30% ++ GAIN IN A WEEK??


**************** EXXA $2.2

Could easily double+ after earnings next week.

http://stockcharts.com/gallery/?EXX/A

The $45M/year DaimlerChrysler contract is starting to kick in in earnest this quarter.

EXXA (symbol EXX/A using Scottrade) will announce 1Q 2006 earnings results in about a 3 weeks.

Target: $4++ After earnings

EXXA will likely post a substantial increase in revenues and net income compared to 1Q 2005. This is because EXXA has started production of powertrains for DaimlerChrysler per the $40M/year long-term contracts announced by EXXA during the later part of 2005.

EXXA HIGHLIGHTS:

* LOW FLOAT = 4.7 MILLION SHARES
* 2005 REVENUES = $147 MILLION
* FORMARD P/E = 5
* PRICE TO SALES = 0.15
* O/S SHARES = 11.3 MILLION
* MARKET CAP = $24MILLION
* INSIDERS OWN 54% OF COMPANY
* HEAVY INSIDER BUYING


*********** DYNT $ 1.7

Target: $2.25 +++ after earnings NEXT WEEK.

http://stockcharts.com/gallery/?dynt

DYNT will likely report very strong numbers for 3Q 2006 during the first week of May.

DYNT is the leader in the area of light therapy for pain management. Light therapy has been approved by the FDA.

One of Dynatronics' light therapy probes were use to accelerate Terrel Owens' amazing recovery in time to play in the Superbowl a couple of years ago.

DYNT has started shipping several new pain-management products in recent months and are expected to boost revenues and net income starting this quarter. DYNT had never before launched so many new products in a year. Revenue and net income usually jump in the quarters following the deployment of new products.

DYNT is grossly undervalued. DYNT is a consistently profitable company with a strong balance sheet. With a parket cap of only $15M, it is currently trading at a ridiculous P/S 0f 0.6.


*****CKSW $1.7 ...EARNINGS May 1, 2006.

http://stockcharts.com/gallery/?CKSW

ClickSoftware (Nasdaq: CKSW) is the leading provider of field service optimization solutions aimed at improving the efficiency and effectiveness of field service operations. CKSW is clearly the leader in this area in the utilities and energy areas.

CKSW has about $14M in cash, or about 50c/share, and ZERO long term debt. Its float of about 13M shares is tighly held because it is just a matter of time until CKSW makes the progress that is expected of it.

On February 08, 2006 CKSW announced that it expects revenues for full year 2006 should grow by approximately 15% over 2005.

CKSW is trading at about 50% valuation compared to sector competitors with less potential and balance sheet problems. CKSW is definitely undervalued IMO.

Institutions have increased their stake in CKSW by over 2M shares (almost 10% of the O/S shares) this year.

CKSW has signed sevearlk large deals in recent months leading me to believe that CKSW will do very well in 2006 and beyond.


DO YOUR DD

CKSW $1,71 REPORTS IMPROVED 1Q 2006 EARNINGS RESULTS

ClickSoftware Reports Financial Results for the First Quarter Ended March 31, 2006
Monday May 1, 7:03 am ET


BURLINGTON, Massachusetts, May 1 /PRNewswire-FirstCall/ -- ClickSoftware Technologies, Ltd., (NasdaqCM: CKSW), the leading provider of workforce and service optimization solutions, today announced results for the first quarter ended March 31, 2006.

For the first quarter ended March 31, 2006, total revenues were $6.5 million, with a net loss of $161,000, or $0.01 per share. This compares with revenues of $6.0 million and a net loss of $639,000, or $0.02 per share, for the same period last year, and revenues of $5.9 million and a net loss of $740,000, or $0.03 per share, for the fourth quarter of 2005. Excluding the effects of share-based compensation expenses related to the adoption of SFAS-123R, net loss this quarter was $64,000, or $0.00 cents per share.

Software license revenues for the first quarter of 2006 were $2.2 million, while service revenues were $4.3 million. This compares to software license revenues of $2.6 million and service revenues of $3.4 million for the same period last year, and $1.7 million and $4.2 million, respectively, in the fourth quarter of 2005.

Gross profit in the first quarter of 2006 was $3.9 million, or 60% of revenues, compared to $3.9 million, or 65% of revenues, in the same period last year, and $3.2 million, or 55% of revenues, in the fourth quarter of 2005.

As of March 31, 2006, the Company had cash, cash equivalents and short and long-term investments of $14.0 million, up by $0.2 million from $13.8 million as of December 31, 2005. Net cash provided from operating activities was $0.2 million during the first quarter of 2006.

"The sequence of wins during 2005 provided the momentum for additional wins at the beginning of 2006. The first quarter was marked by significant developments in three areas that can be expected to positively impact revenue recognized in future quarters. The first is new contracts signed with industry leaders such as one of the world's largest utility companies and a large insurance company under which we expect to receive future orders," said Dr. Moshe BenBassat, Chairman and Chief Executive Officer. "The second is our selection by several major corporations with which we are currently in contract negotiations. And, finally, traction with our business partners - Accenture, IBM and SAP - is getting stronger. As we work together to add large reference clients to illustrate our strong value proposition, we are attracting the attention of new prospects around the world," he added.

Outlook

Based on recent wins and the current pipeline, the Company is reiterating its previous guidance that 2006 revenues will increase by approximately 15% over 2005.

Investor Conference Call

ClickSoftware will host a conference call today at 9:30 a.m. ET to discuss its financial results and other matters discussed in this press release, as well as answer questions from the investment community. To participate, please call (888)-802-2266 and ask for the ClickSoftware conference call. International participants, please call (913)-312-1270. The call will be available live on the internet (in listen mode only) at http://www.clicksoftware.com. A replay of this call will be available on the ClickSoftware website, or by calling (888)-203-1112 (international callers can dial (719)-457-0820), ID Code: 5505004.

DYNT moving up right after the announcement of an earninjgs date....May 4.

Dynatronics to Release Third Quarter Results Thursday, May 4, 2006; Conference Call Set for 3:00 p.m. ET

Monday May 1, 11:00 am ET


SALT LAKE CITY, May 1 /PRNewswire-FirstCall/ -- Dynatronics Corporation (Nasdaq: DYNT - News) will release financial results for its third fiscal quarter ended March 31, 2006 at approximately 11:00 a.m. ET on Thursday, May 4, 2006.
Dynatronics has scheduled a conference call for investors later that day at 3:00 p.m. ET to discuss its results for the quarter. Those interested in participating should call (800) 861-4084 passcode: 9921511#.

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets.


HERE IS A DETAILED DD FOR DYNT


DYNT will likely report very strong numbers for 3Q 2006 during the first week of May. The stock has undergone heavy accumulationj and it is not ready to roar:

http://stockcharts.com/gallery/?dynt

DYNT is the leader in the area of light therapy for pain management. Light therapy has been approved by the FDA. One of Dynatronics' light therapy probes were use to accelerate Terrel Owens' amazing recovery in time to play in the Superbowl a couple of years ago.

DYNT has started shipping several new pain-management products in recent months and are expected to boost revenues and net income starting this quarter. DYNT had never before launched so many new products before. Revenue and net income usually jump in the quarters following the deployment of new products.

DYNT is grossly undervalued. DYNT is a consistently profitable company with a strong balance sheet. With a parket cap of only $15M, it is currently trading at a ridiculous P/S 0f 0.6.

Because light therapy is non-invasive and does not have adverse effects, it is an ideal replacement for dangerous drugs like Vioxx, and Celebrex to address Rheumatism and similar types of pain. Light therapy is also used for carpal syndrome and a number of muscle/nerve/bone types of pain.

Light Therapy has been used extensively throughout the world for more than twenty years. Also known as cold laser or phototherapy, Light Therapy is backed by extensive research with over 500 published studies covering a number of soft-tissue injuries, pain, and inflammatory conditions.

DYNT has introduced a number of new state-of-the-art pain management products at the end of last quarter and this quarter:

Dynatronics began shipping three new products during the second quarter, including the Dynatron Xp infrared light pad. This innovative product is 14 times more powerful than infrared light probes currently on the market. It is capable of treating a much larger area than can be treated by competitors' devices. Importantly, it makes unattended patient therapy possible, allowing practitioners to treat multiple patients simultaneously. The other two products introduced during the second quarter were the Dynatron iBox iontophoresis device and the D880Plus infrared light probe.

"Looking ahead to the third quarter, we are pleased to report that we have already begun shipping the Dynatron 702, a stand-alone light therapy device," said Larry K. Beardall, executive vice president of sales and marketing. "The new Dynatron 702 not only simplifies infrared light therapy treatments, but can be combined with our traction device for dual therapy treatments."

An additional third quarter product introduction -- the DX9 combination traction and light therapy system -- also began shipping in January. The new Dynatron DX9 Decompression System combines the benefits of infrared light therapy with decompression therapy for treating back pain. Decompression therapy is commonly used to relieve the pain associated with a number of back problems, including herniated discs, degenerative disc disease, sciatica and pinched nerves.

Other new products currently under development include the Dynatron X3 multiple modality infrared light therapy device, the DX2 proprietary traction device that incorporates unique technology, and the T4 therapy table specially designed for performing traction and decompression therapies. These products will expand the range of decompression and light therapy treatment options for treating back pain.

"The introduction of these state-of-the-art products will give additional impetus to the growth of sales and profits in future quarters," added CEO Cullimore.


Insiders have been loading up lately as you can see in the following link:

http://www.secform4.com/insider/show...y.php?cik=dynt

DYNT WILL REPORT 3Q 2006 EARNINGS MAY 4 AT 11:00 AM EASTERN TIME.

**** TARGET: $2.25++ AFTER EARNINGS ****

* LEADER IN LIGHT THERAPY FOR PAIN MANAGEMENT

* FDA APPROVED PRODUCTS

* NEW PRODUCTS WILL YIELD SUBSTANTIAL GAINS IN REVENUE AND NET INCOME STARTING WITH TOMORROW'S NUMBERS.

* PROFITABLE AND TRADING AT 0.6 P/S

DYNT will likely report very strong numbers for 3Q 2006.

DYNT is the leader in the area of light therapy for pain management. DYNT's Light therapy products are FDA-approved. In fact, it was widely publicized that one of Dynatronics' light therapy probes was use to accelerate Terrel Owens' amazing recovery in time to play in the Superbowl a couple of years ago.

DYNT has started shipping several new pain-management products in recent months and are expected to boost revenues and net income starting this quarter. DYNT had never before launched so many new products before. Revenue and net income usually jump in the quarters following the deployment of new products.

DYNT is grossly undervalued. DYNT is a consistently profitable company with a strong balance sheet. With a parket cap of only $15M, it is currently trading at a ridiculous P/S 0f 0.6.

Because light therapy is non-invasive and does not have adverse effects, it is an ideal replacement for dangerous drugs like Vioxx, and Celebrex to address Rheumatism and similar types of pain. Light therapy is also used for carpal syndrome and a number of muscle/nerve/bone types of pain.

Light Therapy has been used extensively throughout the world for more than twenty years. Also known as cold laser or phototherapy, Light Therapy is backed by extensive research with over 500 published studies covering a number of soft-tissue injuries, pain, and inflammatory conditions.

DYNT has introduced a number of new state-of-the-art pain management products at the end of last quarter and this quarter:

Dynatronics began shipping three new products during the second quarter, including the Dynatron Xp infrared light pad. This innovative product is 14 times more powerful than infrared light probes currently on the market. It is capable of treating a much larger area than can be treated by competitors' devices. Importantly, it makes unattended patient therapy possible, allowing practitioners to treat multiple patients simultaneously. The other two products introduced during the second quarter were the Dynatron iBox iontophoresis device and the D880Plus infrared light probe.

"Looking ahead to the third quarter, we are pleased to report that we have already begun shipping the Dynatron 702, a stand-alone light therapy device," said Larry K. Beardall, executive vice president of sales and marketing. "The new Dynatron 702 not only simplifies infrared light therapy treatments, but can be combined with our traction device for dual therapy treatments."

An additional third quarter product introduction -- the DX9 combination traction and light therapy system -- also began shipping in January. The new Dynatron DX9 Decompression System combines the benefits of infrared light therapy with decompression therapy for treating back pain. Decompression therapy is commonly used to relieve the pain associated with a number of back problems, including herniated discs, degenerative disc disease, sciatica and pinched nerves.

Other new products currently under development include the Dynatron X3 multiple modality infrared light therapy device, the DX2 proprietary traction device that incorporates unique technology, and the T4 therapy table specially designed for performing traction and decompression therapies. These products will expand the range of decompression and light therapy treatment options for treating back pain.

"The introduction of these state-of-the-art products will give additional impetus to the growth of sales and profits in future quarters," added CEO Cullimore.


Insiders have been loading up lately as you can see in the following link:

http://www.secform4.com/insider/show...y.php?cik=dynt

Keep an eye on DYNT the next few days.

DYNT is getting ready to make its move as expected. I expect strong earnings tomorrow...maybe even record numbers. keep an eye on this one.

EARNINGS OUT AT 11:00. I EXPECT AT LEAST 10% REVENUE GROWTH

Chart looks really good too. They said on another board that earnings will be next week. Auone knows anything about this stock? I am doing my DD but i am relatively new investing. Company thinks it is undervalued:

http://biz.yahoo.com/prnews/060803/lath058.html?.v=64

Sounds interesting. I found this spam on this stock at the SIRI board today. I did some cursory checking on the claims and they seem to be right on. Bought a few K because it looks like a low risk investment at these prices. I like the fact that the company has an currrent stock buybback program.

For whatever is worth:

TWO DAYS LEFT THIS MONTH....BIG PRODUCT ANNOUNCEMENT COMING UP

PROFITABLE...STRONG BALANCE SHEET...ONGOING STOCK BUYBACK PROGRAM...TRADING AT 0.5 P/S TARGET: $3++ by YEAR END

During the 4Q CC this month, the company said that it will announce in late September the introduction of its patent-pending DX2, high-margin, new light-therapy pain management product. Expect a 10 - 20% pop when the announcement is made.

Dynatronics (Nasdaq: DYNT) recently reported another profitable year for FY 2006. 2007 is looking like it will be a strong year for DYNT. DYNT's CEO predicted at least 10% revenue growth and a substantial increase in net income.....1Q 2007 will be reported in about 6 weeks:

From the earnings release and CC:

-- DYNT was profitable again. However, revenues and net income were slightly lower than the previous year because of a substantial increase in R&D activities and the effort needed to launch a number of products late in 2006.

-- The effect of the new products on revenues and net income will start showing up in Q1 2007 to be reported in early November.

-- The backlog for the new Dynatronic X3 light therapy unit released during August 2006 (1Q 2007) has been fulfilled. Expect added revenues and net income in 1Q 2007 resulting from it.

-- DYNT will lower R&D expenses by about 5c/share in 2007 from 2006's record levels.

***** DYNT WILL RELEASE THE NEW REVOLUTIONARY PATENT-PENDING DX2 PAIN MANAGEMENT DEVICE THIS MONTH ****.....

-- The company believes the stock is undervalued and has triggered its stock-buyback program. About 50K shares have recently been purchased. DYNT has cash authorized to buy 250K more shares. the company activates its buyback program when the stock dips under $1.3.

-- A new major product will be launched in November 2006. This product works with the new DX2 device.

-- Based on the new product launches and reduced R&D costs, DYNT expects at least a 10% revenue growth and substatially higher net income. I believe net income will range from 10 - 15c/share in 2007.


SELECTED COMPANY COMMENTS FROM 2006 EARNINGS RELEASE and CC


..."New products introduced during the past year include the Dynatron 702, a stand-alone light therapy device, as well as the new DX9 combination traction and light therapy system. The DX9 system combines the benefits of infrared light therapy using the Dynatron 702 with decompression therapy using the Company's TX900 Traction device. This unique combination of modalities has been reported to be highly effective in the treatment of back pain..."

"Looking ahead to fiscal 2007, we are pleased to have begun the year with the July 2006 introduction of the new Dynatron X3 infrared light therapy device," said Larry K. Beardall, executive vice president for sales and marketing. "In addition, we plan to introduce the much anticipated DX2 proprietary traction device later this month. The DX2 incorporates patent-pending technology and will utilize the new T4 treatment table which is specially designed for traction and decompression therapies. The T4 treatment table is scheduled for introduction in November 2006."

The new DX2 is currently undergoing clinical beta testing and has been previewed at several national trade shows. "Interest in the DX2 from practitioners at the national trade shows has been substantial," reported Beardall. "While the development effort has taken longer than anticipated, we believe this innovative approach to treating back pain will prove to be a great benefit to patients."


OTHER DYNT HIGHLIGHTS:

* DYNT IS THE LEADER IN LIGHT THERAPY FOR PAIN MANAGEMENT

* FDA APPROVED and PATENTED PRODUCTS

* NEW PRODUCTS WILL YIELD SUBSTANTIAL GAINS IN REVENUE AND NET INCOME STARTING with 1Q 2007.....

* PROFITABLE AND TRADING AT 0.5 P/S

* STRONG BALANCE SHEET

This one looks good. Earnings is coming up and should be good. ...really good. Expect a 50 to 100% gain from here

I expect a nice rally before and after 1Q 2007 earnings in early November. CEO said during the last CC that DYNT will increase revenues at least 10%. With about 5c/share less R&D expenses in 2007 than in 2006 i expect net income of about 15c/share in 2007. That is worth well over $3 if you ask me.

http://stockcharts.com/gallery/?dynt

Big buyers are lining up on the bid. Once this one breaks $1.31 it will run to $1.75